Amati investors Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Amati investors

AMTX 1.425

-2.4%

Dec 15 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: j rector who wrote (23798)	8/29/1997 1:15:00 PM
From: pat mudge	of 31386

[Dialogue] <<<<Bottom line is--we can only speculate. Anything less than $30/share would be a very bad deal>>> Yes, it's all speculation, but not without merit. I've put my floor somewhat higher and the powers that be know I'm watching like a hawk. One question, who stands the most to lose by not owning Amati? I know in biotechs there are large companies who get into bidding situations simply because they can't afford not to own a certain drug. Is this a possibility? The two names that come to mind are Pairgain and Westell, and there may be others. I don't know where COMS stands because of its USR purchase. I would imagine they've placed their bet and that's that. At any rate, I'm enjoying the debate and hoping the company doesn't get bought out and instead secures financing and moves into the next phase with "Amati" firmly affixed to all those Allegros and Overtures heading out the door. Cheers! Pat

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next